SLC26A9 gene variations may affect the efficacy of lumacaftor and ivacaftor, drugs used in cystic fibrosis treatment, by altering the ion transport activity these drugs seek to correct or potentiate. These genetic differences can influence the dynamics of chloride and bicarbonate transport, impacting CFTR protein functionality which is crucial for the therapeutic effects of these medications.